BASEL (dpa-AFX) - Novartis (NVS) announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx or secukinumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 52, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo.
The trial demonstrated a sustained response and a safety profile consistent with previous clinical trials. No new safety signals were detected, the company said.
Copyright RTT News/dpa-AFX
© 2019 AFX News
